Neuropathic Pain Market Spotlight, 2017-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Neuropathic Pain” report has been added to ResearchAndMarkets.com’s
offering.

This Market Spotlight report covers the neuropathic pain market,
comprising key marketed and pipeline drugs, recent events and analyst
opinion, clinical trials, upcoming events, probability of success,
patent information, a 10-year disease prevalence forecast, and licensing
and asset acquisition deals, as well as presenting drug-specific revenue
forecasts

Key Takeaways

• The report estimates that in 2017, there were 425.2 million prevalent
  cases of neuropathic pain in adults aged 20 years and older worldwide,
  and forecasts that number to increase to 476.2 million prevalent cases
  by 2026.
• Asia is estimated to have had the largest number of prevalent cases in
  2017, driven by population size, while having the lowest prevalence
  proportion (98.1 million cases; 3.20%).
• The marketed drugs in the neuropathic pain space target sodium
  channels, voltage-gated calcium channels, and transient receptor
  potential vanilloid receptor 1. These drugs are administered via the
  oral route, except for Qutenza, which is available as a topical
  formulation.
• The majority of industry-sponsored drugs in active clinical
  development for neuropathic pain are in Phase I. Therapies in
  development for neuropathic pain focus on a wide variety of targets.
  The majority of pipeline drugs in early- and mid-stage development are
  administered orally, with the remainder being intravenous,
  intramuscular, intraarticular, intrathecal, intradermal, subcutaneous,
  and topical formulations.
• A new partnership for V158866 is the only high-impact upcoming event
  in the neuropathic pain space. The overall likelihood of approval of a
  Phase I neuropathic pain asset is 0.9%, and the average probability a
  drug advances from Phase III is 33.3%. Drugs, on average, take 8.8
  years from Phase I to approval, compared to 9.6 years in the overall
  neurology space.
• There have been 25 licensing and asset acquisition deals involving
  neuropathic pain drugs during 2014-19, eight of which occurred in
  2015. The exclusive licensing agreement in 2015 between Depomed and
  Janssen for the acquisition of the US rights to Nucynta for $1.05bn
  was the largest deal during the period.
• The distribution of clinical trials across Phase I-IV indicates that
  the majority of trials have been in the early and mid-phases of
  development, with 69% of trials in Phase I-II, and only 31% in Phase
  III-IV.
• The US has a substantial lead in the number of neuropathic pain
  clinical trials globally. The UK leads the major EU markets, while
  Japan has the top spot in Asia.
• Clinical trial activity in the neuropathic pain space is dominated by
  completed trials. Pfizer has the highest number of completed clinical
  trials for neuropathic pain, with 230 trials.
• Pfizer leads industry sponsors with by far the highest number of
  clinical trials for neuropathic pain, followed by Allergan.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

Subtypes

TREATMENT

Antidepressants

Antiepileptics

Cannabinoids

Opioids

Topical or focal therapies

EPIDEMIOLOGY

Limitations of neuropathic pain prevalence estimates

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

VX-150 for Neuropathic Pain (December 18, 2018)

CNTX-4975 for Neuropathic Pain (November 07, 2017)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

BIBLIOGRAPHY

For more information about this report visit https://www.researchandmarkets.com/r/ny3g4l

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs , Analgesics